Key result
Intravenous administration of NKH477 at 0.5 µg/kg/min significantly improved hemodynamic and clinical conditions in 71.4% of patients with acute heart failure compared to 34.3% in the lower-dose control group.
Why the study?
Does intravenous NKH477 improve hemodynamics and clinical symptoms in patients with acute heart failure?
Population
78 patients with acute heart failure or acute exacerbation of chronic heart failure, age 20-79.
Comparison
NKH477 intravenous administration at 0.5… vs Study 1: lower dose of NKH477 as a substitute…
Design
RCT, randomly assigned, double-blind, placebo-controlled
Follow-up
90 minutes (30 min for Study 1, 60 min for Study 2)
Authors
Loading...
Supports intravenous NKH477 in acute heart failure; confirms hemodynamic and clinical benefit in this multicenter RCT.
RCT (n=78)
Double-blind
Randomized
Yes
Does intravenous NKH477 improve hemodynamics and clinical symptoms in patients with acute heart failure?
Absolute Event Rate: 71.4% vs 34.3%
p-value: p=<0.01
Intravenous NKH477 (colforsin daropate) safely and effectively improves hemodynamics and clinical symptoms in patients with acute heart failure.
Hosoda et al. (1995) conducted an RCT in Acute heart failure (n=78). NKH477 vs. 0.2 µg/kg/min NKH477 (Study 1) / Placebo (Study 2) was evaluated on Percentage improvement in hemodynamic and subjective and objective conditions (p=<0.01). Intravenous administration of NKH477 at 0.5 µg/kg/min significantly improved hemodynamic and clinical conditions in 71.4% of patients with acute heart failure compared to 34.3% in the lower-dose control group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: